A promising outlook of the Cirrhosis market owing to the anticipated launch of emerging drugs by the key companies during the forecast period (2021-30)

Cirrhosis-Market-Insights

DelveInsight’s Cirrhosis market report provides a thorough comprehension of Cirrhosis, historical and forecasted epidemiology, as well as Cirrhosis market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). The report also discusses current Cirrhosis treatment practices and algorithms, Cirrhosis market drivers, Cirrhosis market barriers, and unmet medical needs.

Some of the Important Finding from the Cirrhosis Market Report

  • As per Moon et al. (2019) study, titled “Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis,” an estimated 1.5 billion people globally have Chronic Liver Disease (CLD).
  • According to the Mazumder et al. (2019) study titled “Gender Disparities In Cirrhosis: New Findings In A Large Pretransplant Population”, out of 18,690 patients included 42.6% were female.
  • Cirrhosis has a strong pipeline of emerging key players in the mid-and late stages of clinical development. Genfit, CymaBay Therapeutics, Ocera Therapeutics, Galectin Therapeutics, Grifols Therapeutics, Gilead Sciences, and others are among the potential key players expected to enter the Cirrhosis market in the upcoming years.
  • The FDA granted Breakthrough Therapy designation to Elafibranor (Genfit) in April 2019 for the treatment of Primary Biliary Cirrhosis in adults with inadequate response to UDCA. It also received Orphan Drug Designation by the FDA and the EMA in July 2019.
  • In 2019, the FDA and EMA granted orphan drug designation to MNK-6105/6106 (Ocera Therapeutics). It also received fast track designation by the FDA in 2019.
  • Seladelpar, developed by CymaBay Therapeutics, is a potent, selective, orally active peroxisome proliferator-activated receptor (PPAR) agonist in development for the Primary Biliary Cirrhosis treatment.

Want to know what are the first signs of cirrhosis? Request sample @ Liver Cirrhosis Diagnostic Market

The Cirrhosis market report covers current treatment practices, emerging drugs, individual therapy Cirrhosis market share, and current and forecasted Cirrhosis market Size from 2018 to 2030, segmented by seven major markets. 

Cirrhosis: Overview

Cirrhosis is the severe scarring and poor liver function seen in the final stages of chronic liver disease. Long-term exposure to toxins, such as alcohol, or viral infections, are the most common causes of scarring. The liver shrinks and hardens as a result of cirrhosis. This makes it difficult for nutrient-rich blood from the portal vein to enter the liver.

Cirrhosis Epidemiology Segmentation

The Cirrhosis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Cirrhosis Total Prevalent Cases
  • Cirrhosis Type-Specific Prevalent Cases
  • Cirrhosis Gender-Specific Prevalent Cases 
  • Cirrhosis Diagnosed and Treatable Cases 

Get the complete epidemiology analysis @ Types of Liver Cirrhosis

Cirrhosis Treatment Landscape

Cirrhosis treatment differs depending on the cause and stage of the disease. Treatment with beta-blockers or nitrates (for portal hypertension), Ursodeoxycholic acid, Obeticholic acid, quitting drinking (for cirrhosis caused by alcohol), intravenous antibiotics (to treat peritonitis that can occur with ascites), hemodialysis (to purify the blood of those in kidney failure), lactulose, and a low protein diet (to treat encephalopathy) are generally prescribed. When all other treatments fail, liver transplantation is the last option.

Cirrhosis Market

The Cirrhosis market is expected to witness the launch of upcoming therapies by key pharmaceutical companies including Genfit, CymaBay Therapeutics, Ocera Therapeutics, and several others. 

The launch of Elafibranor, MNK-6105/6106, Seladelpar, and others are anticipated to provide a major push to the growth of the Cirrhosis market size in the forecast period 2021-30 in the 7MM. 

Cirrhosis Pipeline Therapies and Key Companies 

  • Elafibranor: Genfit 
  • Seladelpar: CymaBay Therapeutics
  • Belapectin: Galectin Therapeutics
  • MNK-6105: Ocera Therapeutics

For more information on the pipeline therapies and companies, visit Liver Cirrhosis Treatment Market

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Cirrhosis Key Companies: Genfit, CymaBay Therapeutics, Ocera Therapeutics, Galectin Therapeutics, Grifols Therapeutics, Gilead Sciences, among others. 

Cirrhosis Key Pipeline Therapies: Elafibranor, Seladelpa, Belapectin, MNK-6105, and others.

Cirrhosis Segmentation: By Geography, Cirrhosis drugs

Analysis: Comparative and conjoint analysis of  Cirrhosis emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

1. Key Insights
2. Executive Summary
3. Cirrhosis Market Overview at a Glance
4. Disease Background and Overview: Cirrhosis
5. American Association For The Study Of Liver Diseases (AASLD) Practice Guidelines
6. Recognized Establishments
7. Cirrhosis Epidemiology and Patient Population
8. Country Wise-Epidemiology of Cirrhosis
9. Cirrhosis Treatment and Medical Practices
10. Cirrhosis Marketed Drugs
11. Cirrhosis Unmet Needs
12. Cirrhosis Emerging Drugs
13. Cirrhosis Market Access and Reimbursement
14. Cirrhosis: Seven Major Market Analysis
15. Cirrhosis 7MM Market Outlook
16. Case Reports
17. Cirrhosis Market Drivers
18. Cirrhosis Market Barriers
19. SWOT Analysis
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Know more about report offerings @ Liver Cirrhosis Market 

Related Reports

Primary Biliary Cirrhosis Market

DelveInsight’s “Primary Biliary Cirrhosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Primary Biliary Cirrhosis, historical and forecasted epidemiology as well as the Primary Biliary Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Decompensated Cirrhosis Market

DelveInsight’s “Decompensated Cirrhosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Decompensated Cirrhosis, historical and forecasted epidemiology as well as the Decompensated Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Ascites Market 

Get comprehensive historical and forecast analysis of Ascites Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as BioVie, Noorik Biopharmaceuticals AG, among others.

Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Market

DelveInsight’s “Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis, historical and forecasted epidemiology as well as the Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Liver Disease

DelveInsight’s “Chronic Liver Disease – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Liver Disease, historical and forecasted epidemiology as well as the Chronic Liver Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Pancreatitis Market

Get comprehensive historical and forecast analysis of Chronic Pancreatitis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Aptalis Pharma, Digestive Care Inc., Kangen Pharmaceuticals, AzurRx BioPharma, among others. 

Non Alcoholic Fatty Liver Disease (NAFLD) Market

DelveInsight’s “Non Alcoholic Fatty Liver Disease (NAFLD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology as well as the Non Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Nonalcoholic Steatohepatitis (NASH) Market

DelveInsight’s “Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroparesis Market 

Get comprehensive historical and forecast analysis of Gastroparesis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Allergan, Vanda Pharmaceuticals, CinDome Pharma, Takeda, among others.

Lamellar Ichthyosis Market

Get comprehensive historical and forecast analysis of Lamellar Ichthyosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Timber Pharmaceuticals, Krystal Biotech, Galderma among others.

Get in touch with our Business executive for Competitive Insights, M&A and Due Diligence Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us 

Sandeep Joshi 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Tags: Cirrhosis Treatment, Liver Cirrhosis Treatment Market, Types of Liver Cirrhosis, Cirrhosis Symptoms, Cirrhosis, Liver Cirrhosis, Liver Cirrhosis Market

See Campaign: https://www.delveinsight.com/
Contact Information:
Sandeep Joshi  info@delveinsight.com  +1(919)321-6187

Tags:
Menafn, PR-Wirein, Reportedtimes, IPS, iCN Internal Distribution, Extended Distribution, Research Newswire, English

Contact Information:

Sandeep Joshi 

info@delveinsight.com 

+1(919)321-6187

iCrowdNewswire